NICE publishes guidance for NHS England & Wales use of obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA343] Published today June 2015

You can access full guidance details on the NICE website here:

Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:

they have other conditions that make full-dose fludarabine unsuitable for them and
bendamustine is not suitable for them.
What does this mean for me?

If you have chronic lymphocytic leukaemia, and your doctor thinks that obinutuzumab (with chlorambucil) is the right treatment, you should be able to have the treatment on the NHS.

Obinutuzumab should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking obinutuzumab (with chlorambucil) until you and your doctor decide it is the right time to stop.